ictady 245 mg tabletki powlekane
rivopharm limited - tenofovirum disoproxilum - tabletki powlekane - 245 mg
tenofovir disoproxil stada 245 mg tabletki powlekane
stada arzneimittel ag - tenofovirum disoproxilum - tabletki powlekane - 245 mg
dunotrisin 200 mg + 245 mg tabletki powlekane
alvogen ipco s.a.r.l. - tenofovirum disoproxilum + emtricitabinum - tabletki powlekane - 200 mg + 245 mg
tenofovir polpharma 245 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - tenofovirum disoproxilum fumaras - tabletki powlekane - 245 mg
tenofovir synoptis 245 mg tabletki powlekane
synoptis pharma sp. z o.o. - tenofovirum disoproxilum fumaras - tabletki powlekane - 245 mg
emtricitabine/tenofovir zentiva 200 mg + 245 mg tabletki powlekane
zentiva, k.s. - emtricitabinum + tenofovirum disoproxilum - tabletki powlekane - 200 mg + 245 mg
emtricitabine +tenofovir disoproxil accord 200 mg + 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - emtricitabinum + tenofovirum disoproxilum - tabletki powlekane - 200 mg + 245 mg
delstrigo
merck sharp & dohme b.v. - doravirine, lamiwudyna, tenofowir disoproxil fumarate - infekcje hiv - leki przeciwwirusowe do leczenia zakażeń hiv, kombinacje - delstrigo jest wskazany w leczeniu osób dorosłych zakażonych hiv-1, bez przeszłych lub aktualnych dowodów opór klasy nnrti, lamiwudyną lub tenofowir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
emtricitabine + tenofovir disoproxil accordpharma 200 mg + 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - emtricitabinum + tenofovirum disoproxilum - tabletki powlekane - 200 mg + 245 mg
emtricitabine/tenofovir disoproxil mylan
mylan pharmaceuticals limited - эмтрицитабин, tenofowir disoproxil tymololu - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 i 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 i 5.